Thu, Jan 29, 2015, 3:47 PM EST - U.S. Markets close in 13 mins.


% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • no2sound no2sound Feb 28, 2009 10:29 AM Flag

    Zack - Isis Pharma Maintains a Buy

    Isis Pharma Maintains a Buy

    Posted Fri Feb 27, 10:37 am ET
    Posted By: Jason Napodano, CFA

    We are reiterating or rating on Isis Pharmaceuticals (ISIS) of a Buy and maintaining our price target of $22.

    We believe that antisense technology represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases. In our view, antisense as a platform is today where biologics were 10 years ago.

    The company's leading candidates are mipomersen (w/ Genzyme, GENZ) for high cholesterol and ISIS-113715 for diabetes, along with several other proprietary and partnered programs for oncology, inflammatory disease, asthma, and viral infections. Our financial model forecasts sustained profitability in 2011.

70.00+1.42(+2.07%)3:46 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.